

SUVEN PHARMACEUTICALS LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2020

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars		For the year ended 31st March 2020	For the year ended 31st March 2019
<b>A. Cash flow from operating activities</b>			
Profit before tax		35,759.03	15,786.71
<b>Adjustments :</b>			
Depreciation and amortisation expense		2,368.29	1,149.68
Interest Income		(36.06)	(19.76)
Finance Cost		2,181.26	278.92
Gain on sale of Current Investment		623.12	(16.33)
<b>Operating profit before working capital changes</b>		<b>40,895.64</b>	<b>17,179.22</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>			
Trade Receivables		3,030.59	(8,489.11)
Inventories		(1,777.39)	(1,708.92)
Other non current financial assets		(35.95)	171.58
Other non current assets		(453.73)	2,703.51
Other current financial assets		(9.62)	4.01
Other current assets		1,044.23	(370.65)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>			
Trade Payables		1,748.08	985.36
Long term provisions		236.93	288.58
Short term provision		(23.49)	(273.18)
Other financial liabilities		899.77	(1,751.42)
Other current liabilities		(136.27)	(392.42)
<b>Cash generated from operating activities</b>		<b>45,418.81</b>	<b>8,346.58</b>
Income taxes paid (net of refunds)		8,640.92	3,306.11
<b>Net Cash flows from operating activities</b>	<b>(A)</b>	<b>36,777.89</b>	<b>5,040.46</b>
<b>B. Cash flow from Investing activities</b>			
Payments for Purchase of property, plant and equipment		(9,941.46)	(5,659.03)
Proceeds from sale of Property, plant & equipment		13.43	(19.56)
Changes in Investments		(24,557.68)	-
Sale/(purchase) of mutual funds		(2,984.35)	(689.77)
Bank balances not considered as cash and cash equivalents		(38.61)	(199.36)
Interest received		36.06	19.76
<b>Net cash flow from /( used in) investing activities</b>	<b>(B)</b>	<b>(37,472.62)</b>	<b>(6,547.96)</b>
<b>C. Cash flows from financing activities</b>			
(Repayment)/Proceeds from long term borrowings		9,125.25	5,203.03
(Repayment)/Proceeds from short term borrowings		1,124.44	(24.64)
Finance Cost		(1,906.88)	(278.92)
Changes In Lease Liability		91.59	-
Dividends paid to equity holders (including dividend distribution tax)		(7,672.29)	(2,301.69)
<b>Net cash flow from /(used In) financing activities</b>	<b>(C)</b>	<b>762.11</b>	<b>2,597.78</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>67.38</b>	<b>1,090.28</b>
Cash and cash equivalents as at the beginning of the year (Refer Note 5(e) (i) )		1,090.30	-
<b>Cash and cash equivalents at the end of the year</b>		<b>1,157.68</b>	<b>1,090.28</b>
Cash and cash equivalents ( Refer Note 5(e)(i))		1,157.68	1,090.30
Balances per statement of cash flows		<b>1,157.68</b>	<b>1,090.30</b>

For Suven Pharmaceuticals Limited

Venkateswarlu Jasti  
Chairman & Managing Director  
DIN: 00278028

Place : Hyderabad

SUVEN PHARMACEUTICALS LIMITED

Consolidated Statement of Cash flows for the year ended 31st March, 2020

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars		For the year ended 31st March 2020	For the year ended 31st March 2019
<b>A. Cash flow from operating activities</b>			
Profit before tax		40,451.18	15,786.71
<b>Adjustments :</b>			
Depreciation and amortisation expense		2,368.29	1,149.68
Interest Income		(36.06)	(19.76)
Finance Cost		2,306.60	278.92
Gain on sale of Current Investment		623.12	(16.33)
<b>Operating profit before working capital changes</b>		<b>45,713.13</b>	<b>17,179.22</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>			
Trade Receivables		3,030.59	(8,489.11)
Inventories		(1,777.39)	(1,708.92)
Other non current financial assets		(35.95)	171.58
Other non current assets		(453.73)	2,703.51
Other current financial assets		(9.62)	4.01
Other current assets		1,044.23	(370.65)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>			
Trade Payables		1,748.08	985.36
Long term provisions		236.93	288.58
Short term provision		(23.49)	(273.18)
Other financial liabilities		899.40	(1,751.42)
Other current liabilities		(136.27)	(392.42)
<b>Cash generated from operating activities</b>		<b>50,235.93</b>	<b>8,346.58</b>
Income taxes paid (net of refunds)		8,640.92	3,306.11
<b>Net Cash flows from operating activities</b>	<b>(A)</b>	<b>41,595.01</b>	<b>5,040.46</b>
<b>B. Cash flow from Investing activities</b>			
Payments for Purchase of property, plant and equipment		(9,941.46)	(5,659.03)
Proceeds from sale of Property, plant & equipment		13.43	(19.56)
Changes in Investments		(30,738.76)	-
Sale/(purchase) of mutual funds		(2,984.35)	(689.77)
Foreign currency translation reserve		1,501.14	-
Bank balances not considered as cash and cash equivalents		(38.61)	(199.36)
Interest received		36.06	19.76
<b>Net cash flow from /( used in) investing activities</b>	<b>(B)</b>	<b>(42,152.55)</b>	<b>(6,547.96)</b>
<b>C. Cash flows from financing activities</b>			
(Repayment)/Proceeds from long term borrowings		9,125.25	5,203.03
(Repayment)/Proceeds from short term borrowings		1,124.44	(24.64)
Finance Cost		(2,032.22)	(278.92)
Changes In Lease Liability		91.59	-
Dividends paid to equity holders (including dividend distribution tax)		(7,672.29)	(2,301.69)
<b>Net cash flow from /(used in) financing activities</b>	<b>(C)</b>	<b>636.77</b>	<b>2,597.78</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>79.23</b>	<b>1,090.28</b>
Cash and cash equivalents as at the beginning of the year (Refer Note 5(e) (i) )		1,090.30	-
<b>Cash and cash equivalents at the end of the year</b>		<b>1,169.53</b>	<b>1,090.28</b>
Cash and cash equivalents ( Refer Note 5(e)(i))		1,169.53	1,090.30
Balances per statement of cash flows		1,169.53	1,090.30

For Suven Pharmaceuticals Limited

Venkateswarlu Jasti  
Chairman & Managing Director

Place : Hyderabad  
Date : 18.06.2020